BRIDGEWATER, N.J., Aug. 27 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. launched today a new 200 mg single-use vial of its chemotherapy treatment Eloxatin(R) (oxaliplatin injection) for patients who have adjuvant stage III colon cancer and advanced colorectal cancer, which is expected to offer more convenience, efficiency and safety in the preparation of the injectable cancer drug. Previously, Eloxatin(R) had been available in 50 mg and 100 mg single- use vials. The 200 mg vial will be available for order by cancer treatment clinics and hospitals nationwide starting the last week of August 2007 (NDC number: NDC 0024-0592-40).
Eloxatin(R), used in combination with two other chemotherapy medications, 5-fluorouracil and leucovorin (5-FU/LV), is indicated for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor. The indication is based on an improvement in disease-free survival, with no demonstrated benefit in overall survival after a median follow-up of four years. In addition, Eloxatin(R) with 5-FU/LV is approved to treat advanced carcinoma of the colon or rectum. Studies have shown that Eloxatin(R) in combination with 5-FU/LV can prolong survival, shrink tumors, and delay the progression of cancer in some patients with advanced colorectal cancer.
"We developed the Eloxatin(R) 200 mg vial to provide even greater convenience, safety and flexibility," said Frank Clyburn, Vice President and head of the U.S. Internal Medicine and Oncology Business Units at sanofi- aventis. "In 2005, we launched the aqueous formulation of Eloxatin(R), a significant advance in preparation efficiency from the lyophilized powder formulation. Now, with this innovation, we are taking another step forward, demonstrating sanofi-aventis' continued commitment to improving cancer care."
The 200 mg vial provides more convenience because of a single vial use
for the majority of patient types and efficiency of prepara
Copyright©2007 PR Newswire.
All rights reserved